-
Electronic (PDF)
-
Site License
-
Enterprisewide
ThromboGenics NV - Product Pipeline Review - Q4 2010
Global Markets Direct, December 2010, Pages: 51
ThromboGenics NV – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “ThromboGenics NV - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- ThromboGenics NV - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ThromboGenics NV human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ThromboGenics NV with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ThromboGenics NV’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate ThromboGenics NV’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ThromboGenics NV in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ThromboGenics NV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ThromboGenics NV.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ThromboGenics NV and identify potential opportunities in those areas.
List of Tables
List of Figures
ThromboGenics NV Overview
Key Information
Key Facts
ThromboGenics NV – Research and Development Overview
Key Therapeutic Areas
ThromboGenics NV – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ThromboGenics NV – Pipeline Products Glance
ThromboGenics NV – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ThromboGenics NV Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
ThromboGenics NV–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ThromboGenics NV – Drug Profiles
Ocriplasmin
Product Description
Mechanism of Action
R&D Progress
Ocriplasmin
Product Description
Mechanism of Action
R&D Progress
TB-402
Product Description
Mechanism of Action
R&D Progress
Anti-GPIb
Product Description
Mechanism of Action
R&D Progress
Anti-VPAC
Product Description
Mechanism of Action
R&D Progress
ThromboGenics NV – Pipeline Analysis
ThromboGenics NV – Pipeline Products by Therapeutic Class
ThromboGenics NV Pipeline Products By Target
ThromboGenics NV – Pipeline Products by Route of Administration
ThromboGenics NV – Pipeline Products by Molecule Type
ThromboGenics NV – Recent Pipeline Updates
ThromboGenics NV - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Ocriplasmin
ThromboGenics NV – Company Statement
ThromboGenics NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 30, 2010: ThromboGenics Partners With MSD For Long-Term Commercial Supply Of Microplasmin
Sep 25, 2010: ThromboGenics To Present Results From Second Phase III Trial Of Microplasmin At ASRS And EURETINA Congress
Sep 06, 2010: ThromboGenics Presents Positive Pooled Results From MIVI-TRUST Phase III Program At EURETINA
Sep 01, 2010: ThromboGenics's Microplasmin Meets Primary Endpoint In Second Phase III Trial In Vitreomacular Adhesion
Jul 15, 2010: ThromboGenics Announces Publication Of Positive Microplasmin Phase II Data In Journal Retina
Jul 09, 2010: ThromboGenics And BioInvent Present Positive Results From Phase II VTE Prophylaxis Study With TB-402 At 21st International Congress On Thrombosis
Jun 07, 2010: ThromboGenics Presents New Microplasmin Phase III Data At World Ophthalmology Congress In Berlin
May 06, 2010: BioInvent And ThromboGenics Report Positive Topline Results From Phase II VTE Prophylaxis Study With TB-402
Apr 20, 2010: ThromboGenics' Microplasmin Meets Primary Endpoint In Phase III Trial For Non-Surgical Treatment Of VMA
Dec 16, 2009: ThromboGenics Completes Enrollment Of Second Phase III Trial Study Of Microplasmin For The Treatment Of Eye Disease
Financial Deals Landscape
ThromboGenics NV, Deals Volume Summary, 2004 to YTD 2010
ThromboGenics NV, Deals Summary By Region, 2004 to YTD 2010
ThromboGenics NV, Deals Summary, 2004 to YTD 2010
ThromboGenics NV Detailed Deal Summary
Equity Offering
ThromboGenics Completes Private Placement Of $63 Million
BioInvent International Amends Co-Development Agreement With ThromboGenics
BioInvent International Enters Into Co-Development Agreement With ThromboGenics
Licensing Agreements
BioInvent And ThromboGenics Enter Into An Agreement With Roche
Bharat Biotech Enters Into Licensing Agreement With ThromboGenics
Roche Diagnostics Signs An Agreement With ThromboGenics And Geymonat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
